News | March 01, 2024
Briefs: Eugia Pharma Specialities and Eugia SEZ
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Eugia Pharma Specialities restarts production at terminally sterilized product lines
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
The observations do not pose any risk to site's compliance standards or its business continuity
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
The plant is yet to start commercial operations
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Subscribe To Our Newsletter & Stay Updated
